NASDAQ:RCKTW Rocket Pharmaceuticals (RCKTW) Stock Price, News & Analysis $0.04 -0.01 (-12.41%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock About Rocket Pharmaceuticals Stock (NASDAQ:RCKTW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rocket Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.1452-Week Range$0.02▼$0.15Volume2,886 shsAverage Volume22,579 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare and often fatal inherited diseases. The company utilizes ex vivo lentiviral vector-based approaches to deliver functional copies of genes into patients’ hematopoietic stem cells. By targeting the underlying genetic defects, Rocket aims to provide potentially curative treatments for disorders that currently rely on lifelong supportive care or conventional interventions. Rocket’s pipeline comprises multiple programs in various stages of development, including treatments for Fanconi anemia, primary immune deficiencies such as PNP deficiency and ADA-SCID, as well as metabolic and cardiac conditions like Danon disease and Barth syndrome. Several of these programs have advanced into clinical trials, reflecting the company’s emphasis on accelerating therapies from preclinical proof-of-concept through regulatory milestones. Founded in 2013 and headquartered in New York, Rocket Pharmaceuticals operates primarily in the United States while collaborating with academic and clinical partners across North America and Europe. The company is led by a management team with extensive experience in gene therapy, hematology and rare disease drug development, and it continues to expand its manufacturing and clinical infrastructure to support future growth.AI Generated. May Contain Errors. Read More Receive RCKTW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCKTW Stock News HeadlinesJefferies Sticks to Its Hold Rating for Rocket Pharmaceuticals (RCKT)August 12 at 6:43 PM | theglobeandmail.comNeedham Remains a Hold on Rocket Pharmaceuticals (RCKT)August 12 at 2:32 AM | theglobeandmail.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 14 at 2:00 AM | Brownstone Research (Ad)Rocket Pharmaceuticals Restructures, Lays Off 30% of Workforce to Focus on Cardiovascular, LAD-I Gene TherapiesAugust 1, 2025 | msn.comRocket Pharmaceuticals Gets FDA Designation to Speed Heart-Disease Treatment DevelopmentJuly 17, 2025 | marketwatch.comRocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701July 15, 2025 | msn.comGlorilla to headline Z107.9 Summer Jam 2025 at Rocket ArenaJuly 15, 2025 | msn.comAustralia Fires First HIMARS Long-Range Rocket in War Game With USJuly 14, 2025 | usnews.comSee More Headlines RCKTW Stock Analysis - Frequently Asked Questions How have RCKTW shares performed this year? Rocket Pharmaceuticals' stock was trading at $0.0343 at the start of the year. Since then, RCKTW stock has increased by 5.0% and is now trading at $0.0360. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKTW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RCKTW CIK1281895 Webwww.rocketpharma.com Phone16464409100FaxN/AEmployees240Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RCKTW) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTesla is in troubleThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.